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ABSTRACT  
A Simple, precise, and accurate stability-indicating reversed-phase high-performance liquid chromatography method has been established for 
the simultaneous estimation of rosuvastatin calcium and fenofibrate in combined bulk and tablet formulation. The chromatographic separation 
was performed on reverse phase Princeton (C18) (250 mm x 4.6 mm, 5µ) column with mobile phase as a mixture of water (pH adjusted to 3.0 
with orthophosphoric acid) and acetonitrile in the ratio (40:60) v/v at the flow rate 1.0 ml/min. Detection was carried out at wavelength 240 
nm. The retention time under the optimized condition of Rosuvastatin calcium and Fenofibrate was found to be 2.485 & 3.905 minutes 
respectively. The calibration curve was linear in the range of 6-16 µg/ml and 87-232 µg/ml for rosuvastatin calcium and fenofibrate with a 
correlation coefficient of 0.9999 and 0.9994 respectively. Relative standard deviation values for all key parameters were less than 2.0%. The 
percentage recovery was found to be 99.66-100.37% and 99.13-100.44% for rosuvastatin calcium and fenofibrate respectively. The developed 
reversed-phase high-performance liquid chromatography method was found to be simple, specific, sensitive, rapid, linear, accurate, precise, 
and economical, and could be used for regular quality control of rosuvastatin calcium and fenofibrate in bulk and tablet formulations.   
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INTRODUCTION 
Rosuvastatin calcium (RSV), is chemically (3R,5S,6E)-7-[4-
(4-fluorophenyl)-6-(1-methylene)-2[methyl (methyl 
sulphonyl amino)]-5pyrimidinyl]-3,5-dihydroxy-6-heptenoic 
acid calcium (Fig. 1). It is a synthetic lipid-lowering agent 
that blocks the production of cholesterol in the body, it is a 
competitive 3-hydroxy-3-methyl-glutaryl coenzyme-A 
reductase inhibitor effective in lowering LDL cholesterol and 
triglycerides, developed for the treatment of dyslipidemia 1,2. 
Fenofibrate (FEN), is chemically propan-2-yl 2-{4-[(4-
chlorophenyl) carbonyl] phenoxy} methyl propanoate (Fig. 
2). It is mainly used to decreased cholesterol levels in 
patients at risk of cardiovascular disease. Like other fibrates, 
it reduces low-density. lipoprotein (LDL) and very-low-
density lipoprotein (VLDL) levels, as well as increasing high-
density lipoprotein (HDL) levels and reducing triglycerides 
levels. The drug is white to white-off powder, soluble in 
dimethylformamide, dimethyl sulfoxide, acetone, acetonitrile 
slightly soluble in water and methanol 3-5. An extensive 
literature survey revealed that several HPLC should be 
methods were reported for the estimation of rosuvastatin 
calcium and fenofibrate in bulk and tablet formulation 6-17. 
The International Conference on Harmonization (ICH) 
guideline entitled “Stability testing of new drug substances 
and products” requires that stress testing be administered 
to elucidate the inherent stability characteristics of the active 
substance 18. An ideal stability-indicating technique is one 
that resolves the drug, and its degradation products 
efficiently. Consequently, the implementation of an analytical 
methodology to work out RSV and FEN, in the presence of its 
degradation products is sort of a challenge for 
pharmaceutical analysts. Therefore, it was thought necessary 
to study the stability of RSV and FEN under acidic, alkaline, 
hydrolytic, oxidative, light, and thermal conditions. The 
reported method has the drawbacks of long runtime and less 
economical with a high proportion of organic phase. Hence, 
an attempt was made to develop reversed-phase high-
performance liquid chromatography (RP-HPLC) which is a 
simple, rapid, accurate, precise, specific, economical, and 
sensitive method for the estimation of rosuvastatin calcium 
and fenofibrate in combined bulk and tablet dosage form. 
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Figure 1: Chemical structure of rosuvastatin calcium 
(RSV) 
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Figure 2: Chemical structure of fenofibrate (FEN) 
MATERIALS AND METHODS 
Chemicals and Reagents  
Pharmaceutical grade Rosuvastatin Calcium and Fenofibrate 
were procured as a gift sample from Cadila Pharmaceuticals 
Ltd., Ahmedabad (India), Zyrova F-10 a tablet formulation, 
obtained commercially.  
Acetonitrile, methanol, orthophosphoric acid, hydrochloric 
acid, sodium hydroxide, and hydrogen peroxide 30% of 
analytical grade were used throughout the work. 
Instrumentation  
Shimadzu HPLC system and PDA detector with Lab Solution 
software were used. 
Chromatographic Conditions 
Chromatographic separation was achieved on a reverse-
phase column Princeton C18 (250 mm × 4.6 mm, 5μ) at 
ambient temperature using a mobile phase consisting of a 
mixture of buffer (pH 3.0, adjusted with orthophosphoric 
acid) and acetonitrile in the ratio of (40:60) v/v at a flow rate 
of 1.0 ml/min. Detection was carried out at 240 nm. The pH 
of the mobile phase was set at 3.0, Injection volume was 10 
μl. The results of the optimized chromatographic condition 
are shown in Table 1. 
  
 
Table 1: Optimized chromatographic condition 
Chromatographic condition 
Mobile phase 
Flow rate 
 Water (pH adjusted to 3.0 with ortho phosphoric acid):Acetonitrile (40:60) v/v 
1.0 ml/min. 
Princeton C18 (250 mm × 4.6 mm, 5μ)  
240 nm 
30 oC 
10 µl 
20 minutes 
Acetonitrile:Water (50:50) 
About 2.485 minutes for Rosuvastatin calcium peak & 3.905 minutes for Fenofibrate peak 
Column  
Detector wavelength 
Column temperature 
Injection volume 
Runtime  
Diluent  
Retention time 
 
 
 
Preparation of standard solution of RSV and FEN 
For RSV, an accurately weighed 1.0 mg of RSV was 
transferred to a 10.0 ml volumetric flask and dissolved in 5.0 
ml of diluent. The volume was completed to 10.0 ml with 
diluent. One milliliter of the resulting solution was pipetted 
in 10.0 ml volumetric flask and the volume was made up to 
10.0 ml with diluent to furnish a solution of concentration 10 
μg/ml of RSV. 
For FEN, an accurately weighed 14.5 mg of FEN was 
transferred to a 10.0 ml volumetric flask and dissolved in 5.0 
ml of diluent. The volume was completed to 10.0 ml with 
diluent. One milliliter of the resulting solution was pipetted 
in 10.0 ml volumetric flask and the volume was made up to 
10.0 ml with diluent to furnish a solution of concentration 
145 μg/ml of FEN. 
For the working mixed standard solution, an accurately 
weighed 1.0 mg of RSV and 14.5 mg of FEN were transferred 
to a 10.0 ml volumetric flask and dissolved in 5.0 ml of 
diluent. The volume was completed to 10.0 ml with diluent. 
One milliliter of the resulting solution was pipetted in 10.0 
ml volumetric flask and the volume was made up to 10.0 ml 
with diluent to furnish a solution of concentration 10 μg/ml 
and 145 μg/ml of RSV and FEN respectively.  
Preparation of sample solution of RSV and FEN 
Twenty tablets were weighed and finely powdered. An 
accurately weighed amount of powder equivalent to 1.0 mg 
of RSV and 14.5 mg of FEN was transferred into a 10.0 ml 
volumetric flask. Then 5.0 ml of diluent was added in it. The 
flask contents were sonicated for 10 min to make the 
contents homogeneous. This solution was then diluted up to 
the mark with diluent. The resultant solution was filtered 
through Whatman Grade I filter paper. One milliliter of the 
filtrate was transferred to a 10 ml volumetric flask and then 
the volume was made up to the mark with diluent to furnish 
a sample solution containing 10 μg/ml of RSV and 145 μg/ml 
of FEN. Six replicate of tablet powder equivalent to 1.0 mg of 
RSV and 14.5 mg of FEN were transferred into six 10.0 ml 
volumetric flask and homogeneous sample solutions were 
prepared similarly. 
Method Validation 
The developed method was validated following ICH 
guidelines (ICH Q2R1) for accuracy, precision, specificity, 
linearity, limit of detection (LOD), limit of quantification 
(LOQ), robustness 19. 
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Stress studies and specificity: 
Stress testing of drug substances can help to identify the 
likely degradation products, which can, in turn, help to 
work out the degradation pathways and thus the intrinsic 
stability of the drug substances. Specificity is the ability of 
the method to measure the responses of the analyte in the 
presence of its related substances. All stress degradation 
studies were performed at initial drug concentrations of 0.1 
mg/ml for RSV and 1.45 mg/ml for FEN. Acid hydrolysis was 
performed in 0.1N HCl at 80˚C for 24 hours. Alkali hydrolysis 
was performed in 0.1N NaOH at 80˚C for 24 hours. Neutral 
hydrolysis was performed at 80˚C for 24 hours.  Oxidation 
studies were conducted at room temperature in 30% 
hydrogen peroxide for 24 hours. For photodegradation 
studies, the drug sample was exposed to sunlight for 30 days. 
Thermal hydrolysis was performed on the sand bath at 50oC 
for 24 hrs. Samples were withdrawn at appropriate times 
and subjected to HPLC analysis after suitable dilution to 
evaluate the ability of the proposed method to separate RSV 
and FEN from their degradation products. 
System Suitability: 
Specificity is the ability of the method to measure the 
responses of the analyte in the presence of its related 
substances. The suitability of the system was demonstrated 
by assessing various parameters. It was established by 
injecting six replicate injections of the standard solution. 
Theoretical plates were found to be 3636 and 4997, tailing 
factor of 1.30 and 1.45, and %RSD of peak area was 0.9 for 
both RSV and FEN respectively. 
Linearity 
Linearity test solutions of RSV and FEN were prepared at 
concentration levels of 6-16 µg/ml and 87-232 µg/ml 
respectively. Linearity test solutions were prepared by 
diluting the stock solution to the required concentrations. 
Linearity was established by the least-squares linear 
regression analysis of the calibration data. Peak areas were 
plotted against the respective concentrations and linear 
regression analysis performed on the resulting curves. The 
linearity curve for RSV and FEN was summarized by Fig. 3 
and Fig. 4 respectively. 
Precision 
The system precision was evaluated by measuring the area 
of six qualified working standards for RSV and FEN 
calculating the percentage of relative standard deviation 
(RSD). The assay method precision was evaluated by 
conducting six independent assays of test samples of RSV 
and FEN against qualified working standards and calculating 
the percentage of relative standard deviation (RSD).  
Accuracy 
The accuracy of an analytical procedure expresses the 
closeness of agreement between the value, which is 
accepted either as a typical true value or an accepted 
reference value, and thus, the value found. It was 
computed at three different levels, i.e., 80, 100, and 120% 
of the label claim. Standard addition and recovery 
experiments were conducted to determine the accuracy of 
RSV and FEN for the quantification of drugs in the samples. 
LOD and LOQ 
The LOD is the lowest analyte concentration that can be 
detected. LOQ is the lowest analyte concentration that can be 
quantified with acceptable accuracy and precision. The limits 
of detection (LOD) and quantification (LOQ) were calculated 
from the standard deviation of the response and the slope of 
the calibration plot. LOD and LOQ were established, 
following ICH definitions, by use of the equations LOD = 
3.3σ/S and LOQ = 10σ/S, where σ is the standard deviation 
of the regression line and S is the slope of the calibration 
plot. 
Robustness 
To evaluate the robustness of the developed method, the 
chromatographic conditions were deliberately altered and 
the resolution between RSV and FEN was evaluated. To study 
the effect of wavelength on the estimation, the wavelength 
was altered by ± 2 nm, i.e., 238 and 242 nm from the actual 
wavelength, 240 nm. To study the effect of flow rate on 
estimation, the flow rate was altered by ± 0.1 ml/min i.e., 0.9 
and 1.1 ml/min from the actual flow rate, 1.0 ml/min.  
RESULTS AND DISCUSSION 
HPLC method development and optimization 
Initially, pure drugs solution was chromatographed using a 
mobile phase consisting of a mixture of buffer (pH 3.0, 
adjusted with orthophosphoric acid) and acetonitrile in the 
ratio of (40:60) v/v at a flow rate of 1.0 ml/min. gives well-
resolved peaks of drugs. Detection was carried out at 240 
nm. The retention time under the optimized condition of 
rosuvastatin calcium and fenofibrate was found to be 2.485 
min. & 3.905 min. respectively. The total run time of the 
chromatogram was about 20 minutes. A typical 
chromatograph of a mixture of standard and sample 
rosuvastatin calcium and fenofibrate is summarized by Fig. 5. 
and Fig. 6 respectively. 
 
Figure 3: Linearity curve of rosuvastatin calcium 
 
Figure 4: Linearity curve of fenofibrate
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Figure 5: Chromatograph of mixture of standard Rosuvastatin calcium and Fenofibrate 
 
Figure 6: Chromatograph of mixture of sample Rosuvastatin calcium and Fenofibrate 
 
Validation of the method 
System Suitability: 
The suitability of the system was demonstrated by assessing 
various parameters. It was established by injecting six 
replicate injections of the standard solution. Theoretical 
plates were found to be 3636 and 4997, tailing factor of 1.30 
and 1.45, and %RSD of peak area was 0.9 for both RSV and 
FEN respectively (Table 2). All the system suitability 
parameters were well within the limits, indicating that the 
system was well suitable for performing the analysis.
  
Table 2: System suitability results 
 
 
 
 
 
 
 
Rt: Retention time, %RSD: Percentage relative standard deviation 
 
Linearity 
Linearity was established by the least-squares linear 
regression analysis of the calibration data. Calibration 
plots were linear over the concentration range of 6-16 
µg/ml for RSV and 87-232 µg/ml for FEN. Peak areas were 
plotted against the respective concentrations and linear 
regression analysis performed on the resulting curves. The 
linear curve of rosuvastatin calcium and fenofibrate was 
shown in Fig. 3 and Fig. 4 respectively. The linear 
regression equation obtained was Y=44776x+40116 for 
RSV and Y=415.83x+557.22 for FEN with correlation 
coefficient 0.9999 and 0.9994 respectively. The results of 
linearity are shown in Table 3.  
Table 3: Linearity results 
 
 
Parameter  RSV FEN 
Theoretical Plate 
Retention Time (Rt) 
Tailing factor 
Resolution 
% RSD 
 3636  
2.485 
1.30 
2.115 
0.9 
4997  
3.905 
1.45 
6.874 
0.9 
Parameter RSV FEN 
Concentration Range (µg/ml) 
Slope (m) 
Intercept 
Coefficient correlation (r2) 
6-16 
44776 
40116 
0.9999 
87-232 
415.83 
557.22 
0.9994 
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Accuracy 
Accuracy was computed by recoveries studies. The mean 
percentage recoveries values for three levels were found to 
be between 99.66-100.37%cand 99.13-100.44% for RSV and 
FEN respectively. The percentage of recoveries values within 
the limits, indicating the method developed was accurate. 
The results of recovery are shown in Table 4. 
 
Table 4: Recovery results 
Drug Level (%) Amount taken 
(µg/ml) 
Amount found* 
 (µg/ml) 
% Recovery* 
 
RSV 
 
80 
100 
120 
     8 
10 
12 
7.99 
9.96 
12.04 
99.98 
99.66 
100.37 
 
FEN 
80 
100 
120 
  116 
 145 
 174 
116.51 
143.74 
172.55 
100.44 
99.13 
99.16 
*Average of three determinations 
 
Precision 
The results of intraday precision and interday precision 
were 0.9 and 0.6 for RSV. The results of intraday precision 
and interday precision were 0.9 and 0.8 for FEN.  The 
percentage RSD of system, method, and intermediate 
precision study was well within the limits (<2%), indicate 
that the method was precise. 
LOD and LOQ 
The LOD was found to be 0.33 µg/ml. for RSV and 16.51 
µg/ml. for FEN. The LOQ was found to be 1.00 µg/ml. for RSV 
and 50.05 µg/ml. for FEN. The values of LOD and LOQ 
indicate that the method was greatly sensitive (Table 7). 
Robustness 
The robustness of the method was designed by changing the 
optimized condition adequately. To evaluate the robustness 
of the developed method, the chromatographic conditions 
were deliberately altered and the resolution between RSV 
and FEN was evaluated. On the assessment of the result it 
can be deduced that the variation in the changing 
wavelength, the flow rate does not affect the method 
significantly. %RSD <2% specifies that the developed 
method was robust. The results of robustness are shown in 
Table 5.  
 
Table 5: Robustness results 
Condition 
RSV FEN 
Amount estimated* [%]  
RSD 
[%] 
Amount estimated* [%]  
RSD 
[%] 
Change in wavelength 
(240±2 nm) 
238 nm 97.28 0.5698 100.16  0.0900 
242 nm 98.21 0.5733 100.08   0.1417 
Change in flow rate  
(1.0±0.1 ml/min) 
0.9 ml/min 99.55  0.6381 99.37  0.2068 
1.1 ml/min 99.24  0.5078 99.56   0.2009 
*Average of three determinations, %RSD: Percentage relative standard deviation 
 
Analysis of rosuvastatin calcium and fenofibrate from 
marketed tablets 
The percentage assay of tablet formulation was found to be 
98.69 and 99.96% for RSV and FEN respectively. The 
stability of the drug solutions was observed for 24 h. In 
degradation studies, the drug was exposed to various stress 
conditions. From the chromatograms of stressed samples, it 
was found that no interference from degradants was 
observed at the retention time of rosuvastatin calcium and 
fenofibrate. Optimum degradation was observed in the 
presence of acid and alkali. Substantial degradation was 
observed in the presence of water, light, and peroxide. No 
degradation was observed in the presence of peroxide and 
thermal for RSV and thermal for FEN. The results of the 
percentage of degradation are presented in Table 6 and Fig. 
7-12. Hence, the method was found to be specific.  
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Fig. 7: Chromatogram of RSV and FEN degraded with acid hydrolysis 
 
 
Fig. 8: Chromatogram of RSV and FEN degraded with alkali hydrolysis 
 
 
Fig. 9: Chromatogram of mixture of RSV and FEN degraded with neutral hydrolysis 
 
 
Fig. 10: Chromatogram of RSV and FEN degraded with oxidative hydrolysis 
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Fig. 11: Chromatogram of RSV and FEN degraded with exposed to direct sunlight 
 
Fig. 12: Chromatogram of RSV and FEN degraded with thermal hydrolysis 
Table 6: Stability-indicating method data for RSV and FEN 
Stress condition  RSV 
(% Degradation) 
FEN 
(% Degradation) 
Acidic (0.1 N HCl for 24 hrs.) 
Alkaline (0.1 N NaOH for 24 hrs.) 
Hydrolytic (HPLC waters for 24 hrs.) 
Oxidative (30% H2O2 for 24 hrs.) 
Photo (Sun light for 30 days) 
Thermal (Sand bath at 50oC for 24 hrs.) 
 10.06 
12.96 
8.45 
No degradation  
6.21 
No degradation 
9.29 
8.72 
6.16 
7.82 
1.45 
No degradation 
HPLC: High Performance Liquid Chromatography 
Table 7: Summary of validation parameter 
Parameter   RSV FEN 
Calibration range (µg/ml) 
Optimized wavelength (nm) 
Retention Time 
 6-16 
240 
2.485 
87-232 
240 
3.905 
Regression equation (Y) 
Slope 
Intercept 
Coefficient correlation (r2) 
Precision (% RSD) 
   Intraday 
   Interday 
% Assay* 
LOD (µg/ml) 
LOQ (µg/ml) 
 Y = 44776x+40116 
44776 
40116 
0.9999 
 
0.9 
0.6 
98.69 
0.33 
1.00 
Y = 415.83x+557.22 
415.83 
557.22 
0.9994 
 
0.9 
0.8 
99.96 
16.51 
50.05 
*Average of five determinations, LOD: Limit of detection, LOQ: Limit of quantification 
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CONCLUSION  
The method enables simple, rapid, accurate, precise, specific, 
economical, and sensitive analysis of rosuvastatin calcium 
and fenofibrate in combined bulk and tablet dosage form.  
This method was validated following ICH guidelines. The 
method can, therefore, be used for routine quality control 
analysis rosuvastatin calcium and fenofibrate in bulk and 
tablet dosage form. 
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